As a lawyer who frequently represents bicyclists who are seriously injured in bicycle collisions, including the cyclists who sustained catastrophic brain injuries in the 2008 and 2010 El Tour de Tucson, despite wearing approved bicycle helmets, I paid particular interest of the recall notice of bicycle helmets manufactured by Louis Garneau USA. The recall involves the Louis Garneau P-09 aerodynamic bicycle helmets with model number 1405362. The word "Garneau" is located on both sides of the helmet. Recalled helmets have the manufacture date "Jan. 2014" on a sticker inside the helmet. The reason for the recall is that in cold temperatures, the helmet can fail to protect the wearer from impact injuries. Consumers have been notified to immediately stop using the recalled helmets, which cost between $280 to $350, and return them to Louis Garneau USA for a refund or replacement.
For the fourth consecutive year, Stephen I. Leshner was recently selected by his peers to be honored in 2015′s The Best Lawyers in America© in the practice area of Plaintiffs' Personal Injury Litigation. The Best Lawyers in America© is a resource for both lawyers and consumers in search of legal talent nationwide. The Best Lawyers in America© is based on a peer-review survey in which 50,000 leading attorneys cast nearly 5 million votes on the legal abilities of other lawyers in their practice areas. Lawyers are not required or allowed to pay a fee to be listed.
Drug giants Bayer and Johnson & Johnson face the first lawsuits related to safety concerns for the billion-dollar blood thinner Xarelto, according to Reuters.
The U.S. Food and Drug Administration (FDA) is requiring manufacturers to include a general warning in the drug labeling of all approved testosterone products about the risk of blood clots in the veins. Blood clots in the veins, also known as venous thromboembolism (VTE), include deep vein thrombosis (DVT) and pulmonary embolism (PE). The risk of venous blood clots is already included in the labeling of testosterone products as a possible consequence of polycythemia, an abnormal increase in the number of red blood cells that sometimes occurs with testosterone treatment. Because there have been postmarket reports of venous blood clots unrelated to polycythemia, FDA is requiring a change to drug labeling of all testosterone products to provide a more general warning regarding venous blood clots and to ensure this risk is described consistently in the labeling of all approved testosterone products.
un 19, 2014, 3:54pm MST Updated: Jun 20, 2014, 7:33am MST
General Motors (GM) has recalled 1,367,146 vehicles: the 2005-2007 Chevrolet Cobalt, the 2007 Pontiac G5, the 2003-2007 Saturn Ion, the 2006-2007 Chevrolet HHR, the 2006-2007 Pontiac Solstice and the 2007 Saturn Sky vehicles due to a faulty ignition switch. The defect allows the key to unintentionally slip from the "run" to "off" or "accessory" position while the vehicle is being operated. This problem can occur especially when using heavy key rings, and causes the ignition to turn off and stall while in motion. The stalled engine can turn off power steering and power brakes, making the vehicle difficult to control and creating a hazardous emergency situation. Additionally, with the loss of power, the air bag system is disabled and rendered useless in an ensuing crash. There have been reported to be at least 34 collisions, resulting in 12 fatalaties, caused by this defective product. As part of the recall, GM dealers will be replacing ignition switches and recommend taking non-essential items off key rings until the ignition switch has been replaced.
Endo International PLC agreed to pay $830 Million to settle about 20,000 lawsuits filed by women who say they were injured by transvaginal mesh devices. While not admitting fault, the company said the settlement will cover a substantial majority of the mesh litigation brought against its American Medical Systems subsidiary. This settlement is in addition to the $54.5 Million Endo agreed to pay last year to settle an undisclosed number of TVM cases.
Phoenix personal injury attorney Stephen I. Leshner has been selected to the 2014 Arizona Super Lawyers list, for the seventh consecutive year. Each year, no more than five percent of the lawyers in the state are selected by the research team at Super Lawyers to receive this honor. Super Lawyers, a Thomson Reuters business, is a rating service of outstanding lawyers from more than 70 practice areas who have attained a high degree of peer recognition and professional achievement. The annual selections are made using a patented multiphase process that includes a statewide survey of lawyers, an independent research evaluation of candidates and peer reviews by practice area. The result is a credible, comprehensive and diverse listing of exceptional attorneys. The Super Lawyers lists are published nationwide in Super Lawyers Magazines and in leading city and regional magazines and newspapers across the country. Super Lawyers Magazines also feature editorial profiles of attorneys who embody excellence in the practice of law. For more information about Super Lawyers, visit SuperLawyers.com.
Endo Health Solutions Inc., the parent company of American Medical Systems, Inc., (AMS) is under investigation relating to its pelvic mesh products. The company has received subpoenas from a number of states in the investigation. Endo revealed this information in a SEC filing last month that warned investors that the "strain of pelvic mesh litigation" threatens its unit's women's health business. AMS is facing thousands of lawsuits in multi-district litigations over the products, and said in the filing that the company is now facing investigation by a number of states, and is cooperating with the investigation.
In the just published "Showtime", a book about the Los Angeles Lakers of the 1980's, by best-selling author Jeff Pearlman, I was interviewed about a case I handled a long time ago. While all my cases are important to me and my clients, this case received a disproportionate amount of publicity, if only because of the identity of the Defendant. As reported in the book: